bluebird bio Q1 net revenue $18.6M; 15 patient starts year-to-date; restates prior financials

bluebird bio, Inc.

2024-Q1 EPS reported -$0.36 revenue$18,573,000

Q1 2024 net revenue $18.6M vs $2.4M Q1 2023, driven by ZYNTEGLO revenue increase.
15 patient starts in 2024: 11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA; full-year guidance 85-105 starts.
First LYFGENIA patient start completed; revenue expected in Q3 2024.
Cash $264M (incl. $52M restricted); expects runway through Q1 2026 assuming $50M additional loan tranches.
Restating 2022 and 2023 financials for lease accounting; no impact on cash or revenue.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

bluebird bio, Inc. reported the three months ended March 31, 2024 results: revenue $18.6 million.

Period: the three months ended March 31, 2024
Revenue: $18.6 million
Result: reported results

Exact text from the filing

– 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 – – First quarter 2024 net revenue of $18.6 million – – Management to host conference call today, May 9, 2024 at 8:00 am ET – SOMERVILLE, Mass. – May 9, 2024 – bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”)

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001293971-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.